2023年4月13日 · Drug development in schizophrenia. Schizophrenia affects approximately 24 million people worldwide, and nearly one third of all cases go undiagnosed. Regulators have pushed strategies to improve clinical trial design and cut costs in schizophrenia, and pharma has followed suit with more drug development investment.

2024年6月15日 · Other trials are looking at whether drugs used to treat a different illness might work against the symptoms of schizophrenia. These medicines have already been proven safe in earlier studies.

2025年1月6日 · Although many psychiatrists who care for patients with schizophrenia say Cobenfy is promising, some are cautious. They note that the FDA approval of the twice-a-day capsule was based on two small, short clinical trials, leaving questions about longer-term use, and many people take medication for schizophrenia all their lives.

2024年10月1日 · The ongoing Phase III ARISE trial is a six-week, randomised, double-blind, placebo-controlled, multicentre, outpatient study in patients with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. ... Cobenfy could be the first approved adjunctive therapy for the treatment of schizophrenia. Other drug ...

2025年1月16日 · The drug was approved for the treatment of schizophrenia in adults after two pivotal phase 3 clinical trials reported in 2024. Both trials were 5 weeks in duration, and tested the new drug in a combined sample of over 500 participants with acute schizophrenia (the subjects had been hospitalized).

2024年12月11日 · Schizophrenia is a severe mental disorder that disrupts thought processes, perceptions, emotional responsiveness and social interactions. In September 2024, the FDA approved Cobenfy, an innovative new drug that offers fewer side effects compared to traditional antipsychotic medications used to treat schizophrenia.

2020年4月15日 · Longer and larger trials are necessary to confirm the effects and side effects of SEP-363856, as well as its efficacy relative to existing drug treatments for patients with schizophrenia.

2020年11月10日 · A CDER research team led by the Office of Clinical Pharmacology and Office of New Drugs pooled data from 32 trials of approved schizophrenia drugs representing over 14,000 patients to evaluate two ...

2025年1月13日 · Schizophrenia research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in schizophrenia clinical trials today. ... This trial will study how drugs for schizophrenia can lead to weight gain, and how diet and exercise may help. They will look at how people's brains react to food, and ...

DRUG TRIALS SNAPSHOT SUMMARY: What is the drug for? REXULTI is a drug used for the treatment of schizophrenia. Schizophrenia is a brain disorder characterized by hearing voices, believing other ...